Podcast Summary: The Peter Attia Drive, Episode #384

Title: Special episode — Obicetrapib: The CETP Inhibitor with Cardiovascular Benefits and Potential Alzheimer's Prevention
Date: March 16, 2026
Host: Peter Attia, MD

Episode Overview

In this focused solo episode, Dr. Peter Attia offers a deep dive into Obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor generating excitement in the realms of cardiovascular disease (CVD) management and Alzheimer’s disease (AD) prevention, particularly for individuals carrying the APOE4 gene. The discussion covers the evolution and setbacks of CETP inhibitors, why Obicetrapib represents a significant step forward, how lipid biology links to both heart and brain health, and the implications of recent clinical and biomarker studies.

Key Discussion Points & Insights

1. Background: CETP Biology and Lipoproteins

• Lipoprotein Basics:
  • Cholesterol is hydrophobic and requires lipoproteins for transport in the bloodstream.
  • Two main classes: ApoB-containing (e.g., LDL, linked to atherosclerosis) and ApoA1-containing (HDL, involved in reverse cholesterol transport).
• Reverse Cholesterol Transport:
  • Traditionally thought of as HDL returning cholesterol from tissues to the liver (direct pathway).
  • Important indirect pathway: HDL trades cholesterol esters with LDL in exchange for triglycerides—process mediated by CETP.
  • CETP's role: “A molecular shuttle that exchanges the cholesterol ester in the HDL for the triglyceride molecule in the LDL as part of this indirect reverse cholesterol transport pathway.” (15:10)
• CETP Inhibition Effects:
  • Inhibiting CETP increases HDL cholesterol, reduces LDL cholesterol.
  • Potential to lower ApoB and LP(a), key markers associated with cardiovascular risk.

2. History of CETP Inhibitors: Failed Attempts and Lessons Learned

• Early Enthusiasm:
  • Initial hope: Raising HDL (“good cholesterol”) would reduce CVD risk.
• Key Trials and Setbacks:
  • Torcetrapib (Pfizer): Raised HDL, lowered LDL, but increased mortality due to off-target blood pressure effects.
    • “Drug gets stopped prematurely in 2006 because of increased mortality, which was secondary to it raising blood pressure. Now, this turned out to be an off-target toxicity...” (25:05)
  • Dalcetrapib (Roche): Modest HDL effect, little LDL/ApoB change, no clinical benefit.
  • Evacetrapib (Eli Lilly): Large HDL raise, modest LDL/ApoB/LP(a) reduction, no significant outcome improvements.
  • Anacetrapib (Merck): Modest reduction in coronary events (up to 12% over six years), but concerns about drug accumulation in fat cells led to discontinuation.
• Key Takeaway:
  • Raising HDL alone is not sufficient; meaningful reduction in LDL/ApoB is essential. Mendelian randomization studies support LDL, not HDL, as a causal risk factor.

3. Obicetrapib: What’s Different?

• Improved Efficacy:
  • Robust LDL and ApoB reduction.
  • In Phase 2 trials (Rose, Ocean, Rose 2):
    • LDL reduced by 50–60% (even on background statin/ezetimibe).
    • ApoB dropped 16–30%.
    • LP(a) reduced by a third.
  • “LDL cholesterol fell by an additional 30% three months out, compared to a 3% increase in the placebo group.” (36:35)
• Metabolic Neutrality:
  • Unlike statins, may have a neutral or possibly favorable effect on diabetes risk.
• Potential Approval Timeline:
  • Approved in Europe (where biomarker surrogates are accepted).
  • US approval pending outcomes trial (Prevail).

4. Broadway Study: Cardiovascular and Alzheimer’s-Related Biomarker Results

• Design:
  • Over 2,500 patients with atherosclerotic CVD or familial hypercholesterolemia, on maximum background therapy, randomized to Obicetrapib or placebo.
  • Important pre-specified biomarker substudy for Alzheimer’s risk:
    • Markers measured: P-tau217, P-tau181, GFAP, neurofilament light (NFL), Amyloid-beta ratio.
• Key Results:
  • P-tau217:
    • Placebo: 5% increase over 1 year; Obicetrapib: only 2%.
    • APOE4 carriers: Placebo subgroup, >7% increase; Obicetrapib <1.5%.
  • Older APOE4 carriers (>70):
    • Placebo: +15% P-tau217; Obicetrapib: +6%.
  • APOE4/4 homozygotes (n=29):
    • Placebo: +12.7% P-tau217; Obicetrapib: –8% (over 20% difference!)
    • “In the group on obicetrapib, they actually saw a reduction in P Tau217 by nearly 8%, creating a difference of over 20% between those treatment groups.” (47:04)
  • All other biomarkers (NFL, GFAP, P-tau181, amyloid-beta ratio): All moved favorably, most pronounced in APOE4/4 group.

5. Implications for Brain Health and Alzheimer’s Disease

• Brain Lipid Biology:
  • Brain cholesterol transport is nearly independent, using APOE (not ApoA1/HDL).
  • APOE4 genotype impairs lipid trafficking, raises AD risk (but is not deterministically causal).
• Potential Mechanism:
  • Obicetrapib increases ApoA1/HDL, potentially increases its crossing into the CNS, benefiting those with APOE4 genotypes with impaired lipidation.
  • “By increasing the circulating pool of ApoA1, the CETP inhibitors can increase the availability of functional ApoA1 within the CNS.” (42:30)
• Cautious Optimism:
  • Data is preliminary (biomarker, not outcomes).
  • Effect is most dramatic in APOE4/4, but population size is small (n=29).
  • “This is a biomarker study that was internally coherent and very genotype specific and I think it has very high biologic plausibility.” (49:43)
  • Calls for a multi-year, genotype-stratified outcome trial with cognitive endpoints.

6. Practical Outlook and Next Steps

• If Outcomes Confirm:
  • Obicetrapib could be transformative for patients with high CVD risk and/or APOE4 genotype at risk for AD.
• US patients:
  • Await cardiovascular outcomes data (Prevail trial) before approval.
• Research Needed:
  • Prospective prevention trial in APOE3/4 and 4/4 populations with cognitive and imaging endpoints.

Notable Quotes & Memorable Moments

• On the Emotional Rollercoaster of Alzheimer’s Prevention:

  “If you spend any time thinking about Alzheimer’s disease research, you get pretty familiar with the emotional whiplash that accompanies it.” (02:00)

• On the value of CETP inhibition beyond HDL:

  "The Mendelian randomizations would suggest to us that simply raising HDL cholesterol is not going to reduce cardiovascular events by itself...what matters is the fall of LDL or ApoB.” (19:53)

• On the striking effect in the most at-risk group:

  “In the group on obicetrapib, they actually saw a reduction in P Tau217 by nearly 8%, creating a difference of over 20% between those treatment groups.” (47:04)

• On the need for caution and further study:

  "We have to be cautious because biomarkers don’t necessarily establish clinical benefit. We need more data." (49:43)
  “I'm not suggesting that this is an easy thing to do. I'm just suggesting that if we lived in a parallel universe where resources were unlimited, that's the study you'd do.” (50:32)

• On his own excitement:

  “It's hard for me to mask my personal optimism around this. I love the biological plausibility…This is a drug I'm very excited about.” (50:51)

Important Timestamps

• [01:04] - Introduction and goals for the episode
• [02:00] - Why Obicetrapib and Alzheimer’s risk in APOE4 is exciting
• [10:40] - Lipoprotein biology—HDL, LDL, reverse cholesterol transport
• [19:35] - CETP inhibitor history: lessons from failures
• [36:35] - Obicetrapib’s phase 2/3 trial results: robust LDL, ApoB, and LP(a) lowering
• [42:30] - How brain cholesterol transport works; APOE genetics and Alzheimer’s risk
• [47:04] - Broadway substudy: Alzheimer’s biomarker results and their interpretation
• [49:43] - Cautionary summary and call for further research
• [50:51] - Personal reflections and practical next steps

Summary Table

| CETP Inhibitor | HDL ↑ | LDL ↓ | ApoB ↓ | CV Outcomes | Issues | |------------------------|-------|-------|--------|--------------|----------------------------| | Torcetrapib | +100% | YES | YES | Harm | Off-target BP elevation | | Dalcetrapib | +30% | Nil | Nil | None | No benefit | | Evacetrapib | +100% | ~30% | ~15% | None | Effect size too small | | Anacetrapib | +100% | YES | YES | Modest ↓ | Fat retention; pulled | | Obicetrapib | +125% | 30–60%| 16–30% | Awaited | None known (to date) |

Final Thoughts

Peter Attia’s analysis frames Obicetrapib as a potentially paradigm-shifting therapy not only for secondary CVD prevention but also as the first evidence-backed preventive for Alzheimer’s, specifically in genetically at-risk populations. While the findings are preliminary and require rigorous outcomes trials, the convergent benefits and lack of major metabolic side effects place Obicetrapib in the spotlight for both clinicians and patients invested in the intersection of heart and brain health.

For more details, refer to the linked Broadway study and episode show notes at peterattiamd.com/shownotes